The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Entertainment
  • Health
  • Business
  • Marketing
  • Construction

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • ET&T Adds Senior Technical Voice Engineer to Strengthen Local Team
  • AI Visibility Labs LLC - Dallas Texas - July 16 2026
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • CodesClue: A Trusted AI-Based Software Development Company for Global Businesses
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
  • Valgar LLC Launches The Briefing Room: Education Leaders
  • New Novel WINCE Takes Unflinching Aim at American Gun Culture and Masculinity
  • New Research Puts the Cost of Enterprise Decision Delay at $630 Billion a Year Across the Global 2000

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • The J. Wes Project Celebrates 11 Years of Love, Music & Inspiration
  • Lionheart Holdings and KEO Energy Sign Letter of Intent for Proposed Business Combination
  • MoMojo Records announces new album from Jad Tariq
  • Marcus Christ Announces Singles: "The Hammer Goes Click" and "You Hate Me, I Hate You"
  • Fatal FOMO May be Your Last Roll of the Dice
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
  • Community Partnership Brings Live Theater to 150+ Young People
  • Best Rainbow Baby Charities That Support Bereaved Parents After Pregnancy Loss: A Complete Guide
  • PokerStars & Ladbrokes veteran buys into Finnish news media Rahapelisanomat
  • Former Judge Chris Oldner Honored as Best Lawyer by "D Magazine" for 6th Straight Year
  • Missouri Hemp Businesses File Federal Lawsuit Challenging HB 2641
  • Boston Industrial Solutions Launches New Citrine® SA1-370 Silicone Glue for Permanent Adhesion
  • Northeast Airlines Launches New Asset Management Group
  • AI Visibility Labs LLC - Dallas Texas - July 16 2026
  • NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
  • ET&T Adds Senior Technical Voice Engineer to Strengthen Local Team
  • Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
  • Where Is Your Faith The Movie and Sountrack
  • Bynn Intelligence Ranks #1 in NIST Child Online Safety Evaluation for Ages 13–16

Popular on PennZone

  • Proper Sky Named to the 2026 MSP 501
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Together We Thrive: Kingdom Life Health & Career Fair Unites Faith, Wellness and Opportunity
  • Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • Boston Industrial Solutions Introduces High-Performance Primer for Bonding Liquid Silicone to Epoxy
  • Dentists launch independent platform to help practices choose the right technology
  • 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
  • New "Lakeside Picnic Ride" Package in Japan's Lake Chuzenji region of Nikko: July 1- November 30, 2026

Similar on PennZone

  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us